✦ LIBER ✦

Nordic walking improves mobility in Parkinson's disease

✍ Scribed by Frank J.M. van Eijkeren; Ruud S.J. Reijmers; Mirjam J. Kleinveld; Angret Minten; Jan Pieter ter Bruggen; Bastiaan R. Bloem

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 122 KB
Volume: 23
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.22293

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Nordic walking may improve mobility in Parkinson's disease (PD). Here, we examined whether the beneficial effects persist after the training period. We included 19 PD patients [14 men; mean age 67.0 years (range 58–76); Hoehn and Yahr stage range 1–3] who received a 6‐week Nordic walking exercise program. Outcome was assessed prior to training (T1), immediately after the training period (T2) and—in a subgroup of 9 patients—5 months after training (T3). At T2, we observed a significant improvement in timed 10‐m walking, the timed get‐up‐and‐go‐test (TUG), the 6‐min walking test and quality of life (PDQ‐39). All treatment effects persisted at T3. Compliance was excellent, and there were no adverse effects. These preliminary findings suggest that Nordic walking could provide a safe, effective, and enjoyable way to reduce physical inactivity in PD and to improve the quality of life. A large randomized clinical trial now appears justified. © 2008 Movement Disorder Society

📜 SIMILAR VOLUMES

Backward walking in Parkinson's disease

✍ Madeleine E. Hackney; Gammon M. Earhart 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

## Abstract We walk backward on a daily basis, such as when backing away from the kitchen sink or stepping back from a curb as a swiftly moving bus passes. This task may be particularly difficult for individuals with Parkinson's disease (PD) who often fall as a result of moving or being perturbed i

Nordic poles immediately improve walking

Nordic poles immediately improve walking distance in claudicants

✍ C. Oakley; I. Zwierska; G. Tew; J. Beard; J. Saxton 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Walking along circular trajectories in P

Walking along circular trajectories in Parkinson's disease

✍ Simone Guglielmetti; Antonio Nardone; Alessandro Marco De Nunzio; Marco Godi; Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB 👁 1 views

## Abstract We hypothesized that gait capacities would be more stressed in patients with Parkinson's disease (PD) when walking along curved than straight trajectories, owing to the complex adaptations required for this walking task. Twenty on‐phase patients with PD and 20 healthy subjects walked ey

Walking economy in people with Parkinson

Walking economy in people with Parkinson's disease

✍ Cory L. Christiansen; Margaret L. Schenkman; Kim McFann; Pamela Wolfe; Wendy M. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract Gait dysfunction is an early problem identified by patients with Parkinson's disease (PD). Alterations in gait may result in an increase in the energy cost of walking (i.e., walking economy). The purpose of this study was to determine whether walking economy is atypical in patients with

Walking stability using harmonic ratios

Walking stability using harmonic ratios in Parkinson's disease

✍ Kristin A. Lowry; Ann L. Smiley-Oyen; Andrew J. Carrel; John P. Kerr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract Kinematic changes in Parkinson's disease (PD) gait are well documented; however, upper body dynamics are less understood. Harmonic ratios (HRs) measure the rhythm of trunk accelerations and can be examined in the vertical, anterior‐posterior, and mediolateral planes, providing an indica

Quetiapine improves psychotic symptoms a

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

✍ Jorge L. Juncos; Vicki J. Roberts; Marian L. Evatt; Rita D. Jewart; Colleen D. W 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

## Abstract Twenty‐nine elderly patients who failed treatment with clozapine, risperidone, or olanzapine entered this 24‐week, single‐center, open‐label trial to assess the efficacy of quetiapine (12.5–400 mg/day) for psychosis in patients with Parkinson's disease (PD). Psychiatric, motor, and cogn